Furthermore, as an oral tyrosine kinase inhibitor (TKI), apatinib selectively bound to and highly inhibited VEGFR2, which had become a novel therapeutic option for patients with advanced or metastatic GC as a third-line treatment in China since 2015 [13]. Here, KDR is linked to gastric cancer.